Bayer floats animal health merger with Lilly spinoff Elanco: report

Bayer
Bayer said late last year it would seek an animal health sale to drum up cash in the wake of its mammoth Monsanto buy. (Bayer)

Bayer’s for-sale animal health unit has been stirring up interest among private equity players—but the German pharma may have another buyer in mind.

The company has approached Elanco, spun off by Eli Lilly last year, about a potential tie-up between the two, Reuters reports, citing three unnamed sources. Elanco currently holds the animal health market’s No. 4 spot—behind just Pfizer spinoff Zoetis, Boehringer Ingelheim and Merck—and merging with No. 5 Bayer Animal Health would create a heavyweight contender.

RELATED: With IPO filing, Lilly pulls back the curtain on animal health business Elanco—warts and all

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

There’s a catch, though: Elanco may not have the cash to buy Bayer’s animal health division outright, Reuters notes. While it boasts a market cap of more than $12 billion, it’s also saddled with significant debt that came with it in the Lilly spinoff. As of the end of 2018, that tab totaled $2.5 billion, Elanco said in its annual report (PDF).

“We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful,” it cautioned.

That means Bayer may have to hold onto a stake in the combined company if it wants to pull off a deal—a prospect the drugmaker may not be thrilled with. Through the animal health sales process, it’s trying to drum up cash in the wake of a $63 billion Monsanto buy that’s been heavily criticized by analysts and investors alike. It said it would seek a sale last November amid announcements that it would also cast off some consumer brands and shed 12,000 jobs.

“Bayer is on track with its plans to exit the animal health business. Following a strategic review of exit options, the primary focus is on a sale. However, Bayer also continues to consider all value-maximizing options. We will not be making any further comments at this stage," a spokesman said by email.

RELATED: Bayer's €8B animal health sale stirs up private equity shoppers: FT

Of course, Bayer doesn’t need to tango with Elanco, given the buzz it’s generated among private equity suitors. Last month, the Financial Times listed CVC, Advent International, BC Partners and a Cinven-Permira team as potential bidders that could shell out up to €8 billion on the unit.

According to Reuters’ sources, Bayer still expects to field private equity bids later this year. But it’s pushed back an auction process meant to start in June to scope out its prospects with Elanco, the news service notes.

Even if the two sides can hammer out a deal, though, regulators might not go for it. The U.S. Federal Trade Commission has been cracking down on drugmakers lately, requiring a blockbuster Otezla sell-off from deal partners Bristol-Myers Squibb and Celgene and slapping Roche with multiple delays to its Spark Therapeutics buyout. Both Bayer and Elanco are working with banks to ensure a transaction would get the green light, Reuters’ sources said.

“The single most important thing that sticks out is potential overlap on flea/tick side. We need to dig into this more … especially since that product category for Bayer animal health is in the top 4 products (which constitute >60% of revs),” Evercore ISI analyst Umer Raffat wrote in a Tuesday note to clients.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.